Genetically engineered immune cells target cancer cells that may be responsible for leukemia relapse
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine.
United States Monical Guzman Gail Roboz Emily Henderson Nature Communications Division Of Hematology Medical Oncology
Source: news-medical.net